Enhanced case finding for drug-resistant tuberculosis in Namibia
Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
This study is trying to find out more about drug-resistant tuberculosis in Namibia by looking at where it spreads and how it affects people in certain areas.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2100 (estimated) |
| Sex | All |
| Sponsor | University of Namibia Academic / other |
| Locations | 1 site (Windhoek) |
| Trial ID | NCT05022238 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the drug-resistant tuberculosis (DR-TB) epidemic in Namibia by collecting clinical, epidemiological, geospatial, social network, and laboratory data. It focuses on identifying transmission hotspots in three regions: Khomas, Otjozondjupa, and Ohangwena. Whole genome sequencing will be utilized to analyze the genetic code of Mycobacterium tuberculosis strains, helping to understand the relationships between strains and the genomic variations that contribute to drug resistance. The study includes DR-TB cases, their household members, hospital visitors, and community members in identified hotspots.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals diagnosed with drug-resistant tuberculosis in the specified regions of Namibia.
Not a fit: Patients who do not have drug-resistant tuberculosis or those who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for identifying and managing drug-resistant tuberculosis cases, ultimately reducing transmission rates.
How similar studies have performed: While the approach of using whole genome sequencing in this context is innovative, similar studies have shown promise in understanding and managing tuberculosis outbreaks.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All cases diagnosed with drug-resistant TB in Namibia, in three regions of Khomas, Otjozondjupa and Ohangwena will be included for the first outcome. For the second outcome, all household members of DR-TB cases will be included; all hospital visitors to DR-TB cases will be included and community members at transmission hotspots will be included. Exclusion Criteria: * Anyone who does not give consent to participate.
Where this trial is running
Windhoek
- University of Namibia — Windhoek, Namibia (Recruiting)
Study contacts
- Principal investigator: Mareli Claassens, PhD — University of Namibia
- Study coordinator: Mareli Claassens, PhD
- Email: mclaassens@unam.na
- Phone: 264814482082
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.